LX2006
Gene Therapy Target: FXN, frataxin
Lexeo Therapeutics
Most recent annual filing: 2026-03-30
- Mantle transaction corporate updateNov 16, 2026Mantle transaction corporate update, Nov 16, 2026, routine
- LX3010 / LX3030 LX3050 LX3070Early 2027LX3010 / LX3030 LX3050 LX3070, Early 2027, notable
- Next FA development candidate IND2027Next FA development candidate IND, 2027, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (12 active programs)
LX2020
Gene Therapy Target: PKP2
LX2021
Gene Therapy Target: Cx43, connexin 43
LX2022
Gene Therapy Target: TNNI3, troponin I
LX1001
Gene Therapy Target: APOE4, APOE2
LX1021
Gene Therapy Target: APOE2, APOE4
LX1020
Gene Therapy Target: APOE2, APOE4
LX1004
LX3010
MTL-104LX3030
MTL-707 Small Molecule Target: HDAC
LX3050
MTL-501LX3070
MTL-801 Nucleic Acid Target: TfR1, FXN
Technology platforms
Sf9-baculovirus AAV manufacturing platform
Optimized Sf9 baculovirus suspension-based AAV manufacturing process offering improved scalability and reduced cost while maintaining purity and potency, supporting cardiac genetic medicine programs.
Biotech Distilled coverage (6)
- 2026-09-23 UPDATE: Lexeo Therapeutics (LXEO) - The $8.3 Million Pipeline and the Market’s Shrug 🔒 Paid
- 2026-08-13 UPDATE: Lexeo Therapeutics (LXEO) - The Quiet ATM 🔒 Paid
- 2026-08-06 UPDATE: Lexeo Therapeutics (LXEO) - The FDA Just Graded the Data the Market Failed 🔒 Paid
- 2026-06-15 UPDATE: Lexeo Therapeutics (LXEO) - The Pivotal Protocol Lands, and the FDA Just Dropped the Hardest Endpoint
- 2026-01-12 UPDATE: Lexeo (LXEO) Drops 25%+ on “Positive” Data – Why Did the Market Halt on the LX2020 Readout? 🔒 Paid
- 2025-12-22 Lexeo Therapeutics (LXEO): Scientific Due Diligence for Lead and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.